As per the agreement, Shasun PharmaceuticalsBSE 3.69 % would be able to use the Debiopharm technology for manufacturing synthetic Huperzine-A and commercialise it, Shasun Pharmaceuticals said in a filing to the BSE.
"It underlines our commitment to delivering cutting-edge science in all our processes through our global research and development network," Shasun Pharmaceuticals President Michel Spagnolsaid.
Huperzine-A is a potent and reversible acetylcholinesterase inhibitor and clinical studies have shown a significant improvement in memory deficit and cognitive performance in patients with Alzheimer's disease.
Commenting on the development Debiopharm Group President Mauvernay said: "We are excited to have the opportunity to add value to this technology while contributing to improve people's quality of life."
Shares of Shasun Pharmaceuticals were trading at Rs 68.35 on the BSE in the afternoon trade, up 4.51 per cent from its previous close.